Serum nicotinamide adenine dinucleotide levels through disease course in multiple sclerosis
Authors:
- Nady BraidyNady Braidy
- Chai K. LimCLChai K. Lim
- Ross GrantRGRoss Grant
- Bruce J. BrewBBBruce J. Brew
- Gilles J. GuilleminGilles J. Guillemin
- 1 November 2013
- journal article
- Published by Elsevier in Brain Research
- Vol. 1537, 267-272
Abstract
No abstract availableKeywords
Funding Information
- National Health & Medical Research Council of Australia Capacity Building
- UNSW Faculty of Medicine Research Grant
This publication has 36 references indexed in Scilit:
- Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon-beta doseJournal of Neuroimmunology, 2010
- Mechanism for Quinolinic Acid Cytotoxicity in Human Astrocytes and NeuronsNeurotoxicity Research, 2009
- Tissue-specific regulation of SIRT1 by calorie restrictionGenes & Development, 2008
- Subcellular Compartmentation and Differential Catalytic Properties of the Three Human Nicotinamide Mononucleotide Adenylyltransferase IsoformsJournal of Biological Chemistry, 2005
- Poly(ADP‐ribose)The FEBS Journal, 2005
- Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal DegenerationScience, 2004
- The new life of a centenarian: signalling functions of NAD(P)Trends in Biochemical Sciences, 2004
- Activation of Microglial Poly(ADP-Ribose)-Polymerase-1 by Cholesterol Breakdown Products during NeuroinflammationJournal of Experimental Medicine, 2003
- PARP-1, a determinant of cell survival in response to DNA damageExperimental Hematology, 2003
- An improved cycling assay for nicotinamide adenine dinucleotideAnalytical Biochemistry, 1973